STANDARD TREATMENT WORKFLOW (STW) Hypothyroidism

Anil Bhansali¹, Eesh Bhatia², B Ganpathi³, Maj Gen Narendra Kotwal⁴, Rajesh Rajput⁵, Ravinder Goswami⁶, Subhankar Choudhary⁷, V Mohan⁸

¹Postgraduate Institute of Medical Education and Research, Chandigarh; ²Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow; ³St John's Medical College Hospital, Bengaluru; ⁴Army Hospital Research and Referral, New Delhi; ⁵Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak; ⁶All India Institute of Medical Sciences, New Delhi; ⁷Institute of Post-Graduate Medical Education and Research, Kolkata; ⁸Dr. Mohan's Diabetes Specialities Centre, Chennai

CORRESPONDING AUTHOR

Dr. Anil Bhansali, Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh

Email: anilbhansali endocrine@rediffmail.com

CITATION

Bhansali A, Bhatia E, Ganpathi B, Kotwal N, Rajput R, Goswami R, Choudhary S, Mohan V. Hypothyroidism. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S115-S116. DOI: <u>https://doi.org/10.56450/JEFI.2024.v2i1Suppl.058</u>

This work is licensed under a Creative Commons Attribution 4.0 International License. ©*The Author(s). 2024 Open Access*

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.





Standard Treatment Workflow (STW) HYPOTHYROIDISM

ICD-10-E03.9

Primary hypothyroidism	Congenital hypothyroidism	Central (Secondary) hypothyroidism
Symptoms Fatigue / Weight gain with poor appetite / Dry skin and cold intolerance / Hair loss / Constipation / Hoarseness of voice / Dyspnea / Muscle weakness and cramps / Menorrhagia (later oligomenorrhea or amenorrhea) / Infertility / Difficulty concentration and poor memory / Paraesthesia / Impaired hearing Signs Dry coarse skin / Cool peripheral extremities / Puffy face, hands and feet (myxoedema) / Diffuse alopecia / Goitre / Bradycardia / Peripheral Oedema / Delayed tendon reflex relaxation / Carpel tunnel syndrome / Serous cavity effusions	New born screening (usually asymptomatic)Prolonged icterus / Edema of the eyelids, hands, and feet / Hypotonia / Inactivity / Gestation > 42 wk / Birth weight > 4 kg / Poor feeding / Hypothermia / Abdominal distention / Open posterior fontanelle (> 5 mm)	Mild-moderate symptoms of hypothyroidism / Signs and symptoms of other pituitary deficits / Manifestations of concomitant hypothalamic pituitary disease Clinical manifestation are less pronounced in secondary hypothyroidism as compared to primary hypothyroidism as there may be multiple pituitary hormone deficiencies which can mask the features of hypothyroidism



July/ 2022



Standard Treatment Workflow (STW) HYPOTHYROIDISM ICD-10-E03.9

		ICD-I			
WHEN TO :	SUSPECT H	YPOTHYR	OIDISM ON CLINICAL O	GROUNDS?	
Primary hypothyroidism		Congenital hypothyroidism		Central (Secondary) hypothyroidism	
isymptoms atigue / Weight gain with poor appetite / nd cold intolerance / Hair loss / Constipat loarseness of voice / Dyspnea / Muscle we nd cramps / Menorhagia (later oligomer menorrhea) / Infertility / Difficulty concer nd poor memory / Paraesthesia / Impaire learing igins Dry coarse skin / Cool peripheral extremiti ace, hands and feet (myxoedema) / Diffue lopecia / Goitre / Bradycardia / Peripheral Delayed tendon reflex relaxation / Carpel yndrome / Serous cavity effusions	/ Dry skin tion / veakness norrhea of norrhea of and feet / H Gestation > s 4 kg / Poo Hypotherm se al Oedema		n screening (usually matic)Prolonged icterus of the eyelids, hands, / Hypotonia / Inactivity / 1 > 42 wk / Birth weight loor feeding / rmia / Abdominal n / Open posterior e (> 5 mm)	Mild-moderate symptoms of hypothyroidism / Signs and symptom of other pituitary deficits / Manifestations of concomitant hypothalamic pituitary disease Clinic manifestation are less pronounced in secondary hypothyroidism as compared to primary hypothyroidism as there may be multiple pituitary hormone deficiencies which can mas the features of hypothyroidism	
Billey	vicz scorir	ng for dia	gnosis of Hypothyroi	idism	
symptoms Score	if present		Physical signs		Score if present
learing impairment	1		Slow movement		1
Diminished sweating	1	Periorbital p			
constipation	1		Delayed ankle reflex		1
araesthesia	1		Coarse skin		1
aorseness /eight increase	1	Cold skin			
ry skin	1	Total score:12		omen younger than 55 years	
lypothyroid ≥6 points		Interme	diate 3-5 points		Euthyroid ≤2 points
	E CONFUN		L SUSPICION OF HYPO	THYDOIDICH	
Primary hypothyroidism	C	ongenital l	nypothyroidism	Central (Secondary) hypothyroidism	
Iterpretation vert hypothyroidism - TSH elevated with w FT4 or T4 levels Jbclinical hypothyroidism - TSH elevated ith normal FT4 or T4 levels	Screening - TSH > centile Confirmato < 0.6 ng/ml		50 mU/ L; T4 < 10th ry - TSH > 9 mU/L; FT4 G THERAPY	Interpretat TSH levels no T4 levels	rmal or low with low FT4 or
Primary hypothyroidism			nital hypothyroidism		econdary) hypothyroidism
Levothyroxine 1.6 to 1.8 mcg per kg per day Single dose, fasting status, no calorie intake for 1 hour thereafter Titrate based on TSH levels Elderly and CAD patients: Start with 12.5–25 mcg/d with 12.5 - 25mcg/d incremental dose every 3–4 wk Consider treating subclinical hypothyroidism in presence of - Large goitre / Positive TPO antibody / ASCVD / Heart failure / Dyslipidemia / Infertility / Depression / refractory anaemia / personal or family history of autoimmune disease		Levothy mcg pe dosing powder FT4 leve	Levothyroxine therapy 10 to 15 mcg per kg per day Single daily dosing Given with breast milk in powdered form Titrate based on FT4 levels and TSH levels based on TSH levels		tine 1.3 mcg per kg per day to be initiated only after existing adrenal cy with Hydrocortisone nt as there is risk of g adrenal crisis,
H	OW SHOUL	D THE PAT	IENT BE FOLLOWED U	P?	
Primary hypothyroidism	Co	Congenital hypothyroidism		Central (Secondary) hypothyroidism	
itrate based on TSH levels arget TSH • Young patient's 1–2.5 mU/L • Middle-aged patients 1.5–3 • Elderly patients	TSH • Titrate ba • Target T4 • Target F1 • Target T5	Titrate based on FT4 or T4 levels and TSH - Titrate based on FT4 or T4 levels and T5H - Target T4: 10 to 16 mcg/dl - Target FT4: 1.4 to 2.3 ng/dl - Target T5H: 0.5 to 2 mU/L - Initial follow up at 2 and 4 weeks - Every 1 to 2 months in first 6 months - Every 3 to 4 months from 6 months to 3 years of age - Every 6 to 12 months till growth is complete		Titrate based on FT4 or T4 levels • Target T4 or FT4 Young people - upper half of normal range • Elderly - mid normal range • Once in 3 to 6 months initially, once stable dose is achieved, annual follow up	
	Every 1 to Every 3 to years of a	2 months o 4 months age	from 6 months to 3	follow up	
- 60–70 y: > 6.0 mU/L - 70–80 y: > 7.0 to 8.0 mU/L once in 3 to 6 months initially, once	Every 1 to Every 3 to years of a	o 2 months o 4 months age o 12 month	from 6 months to 3 s till growth is complete	follow up	
- 60–70 y: > 6.0 mU/L - 70–80 y: > 7.0 to 8.0 mU/L ince in 3 to 6 months initially, once table dose is achieved, annual follow up	Every 1 to Every 3 to years of a Every 6 to	2 months o 4 months age o 12 month ABBRE	; from 6 months to 3 s till growth is complete VIATIONS		G: Ultrasound sonoaranhu
• 60–70 y: > 6.0 mU/L	Every 1 to Every 3 to years of a Every 6 to	o 2 months o 4 months age o 12 month ABBRE TPO: Thyr	from 6 months to 3 s till growth is complete	US	5 G: Ultrasound sonography
- 60–70 y: > 6.0 mU/L - 70–80 y: > 7.0 to 8.0 mU/L nce in 3 to 6 months initially, once sable dose is achieved, annual follow up ASCVD: Atherosclerotic cardiovascular of	Every 1 to Every 3 to years of a Every 6 to	2 2 months o 4 months age o 12 month ABBRE TPO: Thyr TSH: Thyr	a from 6 months to 3 s till growth is complete VIATIONS oid peroxidase oid-stimulating hormone	US	5 C: Ultrasound sonography
- 60–70 y: > 6.0 mU/L - 70–80 y: > 7.0 to 8.0 mU/L ince in 3 to 6 months initially, once table dose is achieved, annual follow up ASCVD: Atherosclerotic cardiovascular of	Every 1 to Every 3 to years of a Every 6 to	2 2 months o 4 months age o 12 month ABBRE TPO: Thyr TSH: Thyr REFER	s from 6 months to 3 s till growth is complete VIATIONS oid peroxidase pid-stimulating hormone ENCES	US	

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on higher specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information. (stw.icmr.org.in) for more information. @Department of Health Research, Ministry of Health & Family Welfare, Government of India.